Skip to main content

Table 2 comparison of quality-adjusted life-years amongst cohort 1 and cohort 2 in recurrent or metastatic head and neck cancer patients

From: Impact of cetuximab plus cisplatin alone and cetuximab plus cisplatin and paclitaxel regimen on humanistic outcome in head and neck cancer

Group

Visit

Mean ± SEM (QALYs)

Cohort 1

1

0.016 ± 0.001

2

0.014 ± 0.001

3

0.019 ± 0.001*#

4

0.026 ± 0.001*#$

5

0.025 ± 0.001*#$

6

0.029 ± 0.001*#$@!

Cohort 2

1

0.017 ± 0.001

2

0.016 ± 0.001*

3

0.021 ± 0.001*#

4

0.027 ± 0.001*#$

5

0.032 ± 0.001*#$@

6

0.038 ± 0.001*#$@!

  1. *P < 0.05, compared to V1 of respective group, #compared to V2 of respective group, $compared to V3 of respective group, @compared to V4 of respective group, !compared to V5 of respective group. Data presented as mean ± SEM. Data analyzed by two-way ANOVA followed by Tukey’s multiple comparison test (CI = 95%, P < 0.05)